L
Linda Millar
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 12
Citations - 1720
Linda Millar is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Zidovudine & Selegiline. The author has an hindex of 12, co-authored 12 publications receiving 1650 citations.
Papers
More filters
Journal ArticleDOI
Failure of Cytarabine in Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus Infection
Colin D. Hall,Urania Dafni,David M. Simpson,David B. Clifford,Patricia E. Wetherill,Bruce A. Cohen,Justin C. McArthur,Harry Hollander,Constantin Yainnoutsos,Eugene O. Major,Linda Millar,Joseph Timpone +11 more
TL;DR: Cytarabine administered either intravenously or intrathecally does not improve the prognosis of HIV-infected patients with progressive multifocal leukoencephalopathy who are treated with the antiretroviral agents, nor does high-dose antireTroviral therapy alone appear to improve survival over that reported in untreated patients.
Journal ArticleDOI
A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection
Justin C. McArthur,Constantin T. Yiannoutsos,David M. Simpson,Bruce T. Adornato,Elyse J. Singer,Harry Hollander,Camillo Marra,Michael Rubin,Bruce A. Cohen,Tarvez Tucker,Bradford A. Navia,Giovanni Schifitto,David Katzenstein,C. A. Rask,Lawrence Zaborski,Mary E. Smith,S. Shriver,Linda Millar,David B. Clifford +18 more
TL;DR: A positive effect of recombinant human nerve growth factor on neuropathic pain and pin sensitivity in HIV-associated sensory neuropathy was found and rhNGF was safe and well tolerated, but injection site pain was frequent.
Journal ArticleDOI
Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure
Paul Palumbo,Jane C. Lindsey,Michael Hughes,Mark F. Cotton,Raziya Bobat,Tammy Meyers,Mutsawashe Bwakura-Dangarembizi,Benjamin H. Chi,Philippa Musoke,Portia Kamthunzi,Werner Schimana,Lynette Purdue,Susan H. Eshleman,Susan H. Eshleman,Elaine J. Abrams,Linda Millar,Elizabeth Petzold,Lynne M. Mofenson,Patrick Jean-Philippe,Avy Violari +19 more
TL;DR: Among children with prior exposure to single-dose nevirapine for perinatal prevention of HIV transmission, antiretroviral treatment consisting of zidovudine and lamivudine plus ritonavir-boosted lopinavir resulted in better outcomes than did treatment with zidvudineand lamivUDine plus ne virapine.
Journal ArticleDOI
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
Avy Violari,Jane C. Lindsey,Michael Hughes,Hilda Mujuru,Linda Barlow-Mosha,Portia Kamthunzi,Benjamin H. Chi,Mark F. Cotton,Harry Moultrie,Sandhya Khadse,Werner Schimana,Raziya Bobat,Lynette Purdue,Susan H. Eshleman,Elaine J. Abrams,Linda Millar,Elizabeth Petzold,Lynne M. Mofenson,Patrick Jean-Philippe,Paul Palumbo +19 more
TL;DR: Outcomes were superior with ritonavir-boosted lopinavir among young children with no prior exposure to nevirapine in a randomized trial conducted in six African countries and India.
Journal ArticleDOI
HIV neuropathy natural history cohort study: Assessment measures and risk factors
David M. Simpson,Douglas Kitch,Scott R. Evans,Justin C. McArthur,David M. Asmuth,Bruce A. Cohen,K. Goodkin,Mariana Gerschenson,Yuen T. So,Camillo Marra,Ramon Diaz-Arrastia,S. Shriver,Linda Millar,David B. Clifford +13 more
TL;DR: In this cohort of advanced HIV infection–infected subjects, distal sensory polyneuropathy was common and relatively stable over 48 weeks, and previously established risk factors, including CD4 cell count, plasma HIV RNA, and use of dideoxynucleoside antiretrovirals were not predictive of the progression of DSP.